Skip to content

Early combined use of terlipressin in patients with septic shock: a single center, randomized, controlled trial

Early combined use of terlipressin in patients with septic shock: a single center, randomized, controlled trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000040350
Enrollment
Unknown
Registered
2020-11-28
Start date
2020-12-01
Completion date
Unknown
Last updated
2021-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Septic shock

Interventions

Terlipressin combination:After adequated fluid resuscitation, if the dosage of norepinephrine exceeds 10ug/min, add terlipressin, terlipressin (1mg) was dissolved in a 50-mL syringe containing 5% dext
norepinephrine :After adequate fluid resuscitation, only norepinephrine was used to maintain the target blood pressure

Sponsors

Jiangsu Provincial Hospital on Integrated Traditional Chinese and Western Medicine
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Patients older than 18 years diagnosed with septic shock. Septic shock was defined: proven or suspected infection, and hypotension despite adequate fluid resuscitation (sepsis induced hypotension defined as systolic blood pressure (SBP)40 mmHg below normal for age in the absence of other causes of hypotension). After adequate fluid resuscitation, to maintain blood pressure, the dosage of norepinephrine exceeds 10ug/min.

Exclusion criteria

Exclusion criteria: (1) unstable coronary syndrome (acute myocardial infarction during this episode of shock based on the combination of history, electrocardiogram and enzyme changes; (2) previous use of terlipressin for arterial blood pressure support during the current ICU admission; (3) malignancy or other irreversible disease or condition for which mortality was estimated to be very high (defned by investigator); (4) acute mesenteric ischaemia either proven or suspected; (5) Raynauds phenomenon; (6) pregnancy; (7) organ transplantation.

Design outcomes

Primary

MeasureTime frame
Time to target mean arterial pressure;

Secondary

MeasureTime frame
SOFA;Urine output;Cumulative drug dose;

Countries

China

Contacts

Public ContactHaibin Ni

Jiangsu Provincial Hospital on Integrated Traditional Chinese and Western Medicine

18001580139@126.com+86 15312019183

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026